In Re Vitamin Cases

132 Cal. Rptr. 2d 425, 107 Cal. App. 4th 820, 2003 Cal. Daily Op. Serv. 2923, 2003 Daily Journal DAR 3733, 2003 Cal. App. LEXIS 492
CourtCalifornia Court of Appeal
DecidedApril 3, 2003
DocketA097905
StatusPublished
Cited by12 cases

This text of 132 Cal. Rptr. 2d 425 (In Re Vitamin Cases) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Vitamin Cases, 132 Cal. Rptr. 2d 425, 107 Cal. App. 4th 820, 2003 Cal. Daily Op. Serv. 2923, 2003 Daily Journal DAR 3733, 2003 Cal. App. LEXIS 492 (Cal. Ct. App. 2003).

Opinion

Opinion

HAERLE, J.

I. Introduction

In this appeal, four class members challenge the settlement of a class action complaint, which had been brought against a number of manufacturers of vitamin products. They contend that Code of Civil Procedure section 384 (section 384) bars the settlement because it does not allow the members of their class to make individual claims, instead awarding the entire settlement to charitable and nonprofit organizations. We conclude that section 384 does not bar the settlement in this case and, accordingly, affirm.

II. Factual and Procedural Background

This appeal arises from a coordinated proceeding for numerous separate complaints brought on behalf of a class of “[a]ll purchasers located in the *824 State of California who indirectly purchased vitamins, vitamin premixes, and/or other vitamin products from any of the Defendants for use, but not for resale, at any time during the period January 1, 1988 to” the late 1990’s. The coordinated class complaint (the Class Complaint) alleged that defendants, manufacturers of “raw vitamins . . ., vitamin premixes, and other bulk vitamin products for bulk sales,” committed price fixing in violation of both the Cartwright Act (Bus. & Prof. Code, § 16700 et seq.) and the unfair competition law (Bus. & Prof. Code, § 17200 et seq.).

On October 31, 2000, the Attorney General, acting on behalf of the People of the State of California, filed a complaint, which contained allegations similar to those in the Class Complaint. Seven of the defendants named in the Class Complaint were also named in the Attorney General’s complaint. On November 29, 2000, the trial court granted the People’s petition for coordination of its case as an add-on case to the coordinated proceeding.

On August 29, 2001, the class representatives and the People (collectively plaintiffs) filed a motion for preliminary approval of class action settlement with the seven defendants named in the Attorney General’s complaint: BASF Corporation, Daiichi Pharmaceutical Co., Ltd., Eisai Co., Ltd., Aventis Animal Nutrition S.A. (formerly Rhone-Poulenc Animal Nutrition, S.A.), Hoffman-La Roche, Inc., Roche Vitamins, Inc., and Takeda Chemical Industries, Ltd. (collectively settling defendants). The settlement agreement contemplated a payment of $16 million for attorney fees and the certification of two classes for settlement purposes only. One class, described as the consumer settlement class (Consumer Class), was to consist of “[a]ll natural persons . . . who purchased Indirect Vitamin Products during the Relevant Period for use or consumption by themselves and/or others and not for resale in any form, and who are residents of the State of California.” In settlement of the claims of the Consumer Class, $38 million was to be distributed to charitable, governmental and nonprofit organizations that promote the health and nutrition of consumer class members or that otherwise further the purposes underlying the lawsuit.

The second class, described as the commercial settlement class (Commercial Class), was to consist of certain purchasers of “Indirect Vitamin Products for resale, for incorporation into another product or products for resale, or for use in the manufacture, processing or development of another product (including the feeding of an animal) for resale . . . .” The Commercial Class was to be paid up to $42 million.

The motion explained that notice would be given to the class members by publication and attached a copy of the proposed notice. The notice explained *825 that the “Consumer Settlement Amount (i.e., $38 million minus court-approved costs and expenses, plus interest) will be distributed, pursuant to a court-approved plan of distribution, to eligible organizations that collectively are, as nearly as practicable, representative of the interests of injured consumers. ... [H] The consumer settlement amount will not be paid to individual California consumers for the following four reasons: (a) the impracticability of processing the potential claims of 30 million individuals who purchased Indirect Vitamin Products during the Relevant Period; (b) the expense and inconvenience to individual class members associated with having to document specific purchases of Indirect Vitamin Products over a span of more than ten years; (c) the potential unfairness to class members who are unable to provide evidence of their purchases of Indirect Vitamin Products during the Relevant Period; and (d) the high cost of administering direct cash payments to millions of consumers relative to the average likely award to those consumers.” The notice further explained the process by which class members could opt-out of the settlement.

On September 19, 2001, the trial court gave its preliminary approval of the proposed settlement, including its planned publication of notice. The court scheduled a hearing on “final settlement approval” for January 18, 2002.

On November 14, 2001, appellants, each an alleged member of the Consumer Class, filed a motion for intervention. They sought to object to the settlement of the Consumer Class claims on the ground that the settlement did not provide the members of the Consumer Class an opportunity to obtain their proportionate share of the proposed settlement prior to its allocation to cy pres relief. Appellants further argued that representation of both the Consumer and Commercial Classes by the same attorneys constituted a conflict of interest. On December 21, 2001, the trial court denied the motion for intervention, explaining in part that “[o]n the existing record it has not been shown that class counsel have a prohibited conflict of interest in representing both the consumer class and the commercial class . . . .”

On December 10, 2001, appellants filed objections to the proposed Consumer Class settlement. On January 18, 2002, the trial court filed its “Final Order Approving Consumer Class Settlement And Final Judgment” and “Final Order Approving Commercial Class Settlement And Final Judgment.” With respect to the Consumer Class, the trial court found “that the cy pres distribution of the Consumer Class Settlement proceeds is proper because of the following three reasons: (1) it is impracticable or impossible to compensate direct victims of the alleged wrongdoing because of the disproportionate administrative expenses resulting from the number of potential claimants in *826 relation to the size of the fund; (2) there is a strong correlation between the proposed use of the funds and the class benefited; and (3) the proposed relief furthers the purpose of the relevant statute.” 1

III. Discussion

A. The Propriety of the Cy Pres Remedy

The settlement agreement contemplates distribution of the entire Consumer Class settlement to charitable, governmental and nonprofit organizations. Appellants refer to this remedy as a cy pres remedy. The doctrine of cy pres

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mount v. Wells Fargo Bank CA2/8
California Court of Appeal, 2016
Laffitte v. Robert Half Internat.
California Court of Appeal, 2014
Laffitte v. Robert Half Internat. CA2/7
California Court of Appeal, 2014
Tormey v. The Vons Companies CA4/1
California Court of Appeal, 2014
Litwin v. iRenew
California Court of Appeal, 2014
Litwin v. iRenew Bio Energy Solutions, LLC
226 Cal. App. 4th 877 (California Court of Appeal, 2014)
In re Checking Account Overdraft Litigation
830 F. Supp. 2d 1330 (S.D. Florida, 2011)
Cundiff v. Verizon California, Inc.
167 Cal. App. 4th 718 (California Court of Appeal, 2008)
Schwab v. Philip Morris USA, Inc.
449 F. Supp. 2d 992 (E.D. New York, 2006)
In Re Microsoft I-V Cases
37 Cal. Rptr. 3d 660 (California Court of Appeal, 2006)
Patrowicz v. Transamerica HomeFirst, Inc.
359 F. Supp. 2d 140 (D. Connecticut, 2005)
In Re Vitamin Cases
2 Cal. Rptr. 3d 358 (California Court of Appeal, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
132 Cal. Rptr. 2d 425, 107 Cal. App. 4th 820, 2003 Cal. Daily Op. Serv. 2923, 2003 Daily Journal DAR 3733, 2003 Cal. App. LEXIS 492, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-vitamin-cases-calctapp-2003.